Article Information
History
- July 18, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Xiaolan Yonge,*,
- Jun Liuf,*,
- Ying Zengb,c,*,
- Jing Nief,
- Xuelian Cuid,
- Tao Wangd,
- Yilin Wangd,
- Yiyong Chend,
- Wei Kangb,c,
- Zhonghua Yangb,c and
- Yan Liua,d,✉
- aCollege of Pharmacy, Chongqing Medical University, Chongqing 400016, China
- bGuangzhou Patronus Biotech Co. Ltd., Guangzhou, Guangdong 510320, China
- cYantai Patronus Biotech Co. Ltd., Yantai, Shandong 265719, China;
- dChongqing Medleader Bio-Pharm Co., Ltd., Chongqing 401338, China;
- ePhase I Clinical Trial Center, Chengdu Xinhua Hospital Affiliated to North Sichuan Medical College, Chengdu, Sichuan 610055, China;
- fPulmonary and Critical Care Medicine, Chongqing Red Cross Hospital (People’s Hospital of Jiangbei District), Chongqing 400020, China;
- ↵✉Correspondence to: Dr Yan Liu, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; Email: y.liu{at}cqmu.edu.cn
↵* These authors contributed equally.
Posted July 18, 2023.
Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
